The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency …

Malignant Neoplastic Disease (Disorder)

~Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT07832630

Phase 1

Indocyanine Green (ICG) Guided Tumor Resection

This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the pri…

Neoplastic DiseaseSolid Tumor

~Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT04084067